Adverse effects ‐ hepatic toxicity · chronic rhinosinusitis
Systemic antifungal showed no clear difference in adverse effects ‐ hepatic toxicity compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 3.35 [0.14, 78.6]
Studies not reported
Low
Gastrointestinal adverse events · chronic rhinosinusitis
Systemic antifungal showed no clear difference in adverse effects ‐ gastrointestinal disturbances compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 0.37 [0.04, 3.36]
Studies not reported
Low
Allergic adverse events · chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Generic quality of life measures · chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (HRQL) · chronic rhinosinusitis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Disease severity score · chronic rhinosinusitis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total (all‐cause) mortality · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in total (all‐cause) mortality compared with placebo/no antifungal/any other antifungal (moderate certainty).
1 finding from 1 review
Proven invasive fungal infection · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower proven invasive fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Superficial fungal infection · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in superficial fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Fungal colonization · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower fungal colonization compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Treatment cessation due to adverse events · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in adverse events requiring cessation of study drug(s) compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in systemic fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Incidence of systemic infection · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Health‐related quality of life (HRQL) · chronic rhinosinusitis
Topical antifungal may leads to lower heath‐related quality of life (HRQL) compared with placebo/no treatment (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Disease severity score · chronic rhinosinusitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Generic HRQL (change from baseline) · chronic rhinosinusitis
2 findings from 1 review
no estimate extracted
Studies not reported
Low
no estimate extracted
Studies not reported
Low
Adverse effects ‐ epistaxis · chronic rhinosinusitis
Topical antifungal showed no clear difference in adverse effects ‐ epistaxis compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 0.97 [0.14, 6.63]
Studies not reported
Low
Adverse effects: headache · chronic rhinosinusitis
It is very uncertain whether topical antifungal changes adverse effects ‐ headache compared with placebo/no treatment (very low certainty).
1 finding from 1 review
RR 1.26 [0.6, 2.63]
Studies not reported
Very low
Other adverse effects: local irritation · chronic rhinosinusitis
Topical antifungal showed no clear difference in adverse effects ‐ local irritation compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.29 [0.61, 8.62]
Studies not reported
Low
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs not absorbed from GI tract showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review